Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BUDA vs LMRI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LMRI Wins Head-to-Head Institutional Verdict (0–0 across 6 Pillars · 1–2 Matrix Metrics)

LMRI Overall Winner 6-Pillar Tally: BUDA 0 – 0 LMRI (6 Tie) Matrix Metrics: BUDA 2 – 1 LMRI

As of Nov 20, 2026, LMRI (LMRI) is the stronger overall head-to-head candidate over BUDA (BUDA) in the Tradestie Institutional Equity Comparison Engine, winning 1–2 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). BUDA carries a Unified Composite Score of 34.2/100 (SELL) at $5.30 (N/M Forward P/E, N/A operating margin), whereas LMRI carries 32.1/100 (SELL) at $14.26 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While BUDA currently prints a higher short-term Unified Composite Score (34.2/100 SELL vs. LMRI 32.1/100 SELL), LMRI captures the overall institutional head-to-head verdict (1–2 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).
  • Defensive Composite Rating Caution: Although LMRI compares more favorably head-to-head, both BUDA (34.2/100 SELL) and LMRI (32.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: BUDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.2); meanwhile LMRI trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BUDA vs LMRI
BUDA US Equity
BUDA
Institutional Equity
$5.30
-0.19% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.03β · 71% Vol
Unified Composite Score
34.2 / 100 SELL
Tech 35.0 Fund 42.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 28
RSI-14: 28.2 · SMA20: $6.51 · SMA50: $7.15
LMRI US Equity Head-to-Head Winner
LMRI
Institutional Equity
$14.26
+1.42% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.22β · 85% Vol
Unified Composite Score
32.1 / 100 SELL
Tech 50.0 Fund 30.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.4% over 20 days), RSI 63
RSI-14: 62.5 · SMA20: $13.28 · SMA50: $11.73

6-Pillar Scorecard Institutional Category Breakdown (BUDA 0 – 0 LMRI)

Columns: Metric · BUDA · LMRI
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap N/A N/A
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BUDA (2) vs LMRI (1)
Institutional Metric BUDA LMRI Criterion Row Edge
Market Capitalization
Scale
N/A N/A Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
1% ($5–$12) 60% ($6–$19) Stronger Trend LMRI
Beta / 30D Volatility
Risk Regime
-0.03β · 71% Vol 1.22β · 85% Vol Lower Realized Risk BUDA
Unified Institutional Score
Composite Signal
34.2 / 100 (SELL) 32.1 / 100 (SELL) Higher Composite BUDA
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LMRI +51.85 pp
BUDA: -20.9% · LMRI: +30.95%
3M Horizon LMRI +63.42 pp
BUDA: -41.33% · LMRI: +22.09%
6M Horizon LMRI +130.71 pp
BUDA: -38.01% · LMRI: +92.7%
1Y Horizon LMRI +15.08 pp
BUDA: -34.65% · LMRI: -19.57%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BUDA vs LMRI. Trailing 12-month operating profitability (BUDA N/A vs LMRI N/A) and valuation multiples (BUDA N/M vs LMRI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

BUDA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
LMRI ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BUDA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BUDA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LMRI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LMRI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BUDA Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LMRI Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BUDA vs LMRI Key Questions & Quantitative Answers

As of Nov 20, 2026, LMRI (LMRI) is the stronger overall head-to-head candidate over BUDA (BUDA) in the Tradestie Institutional Equity Comparison Engine, winning 1–2 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). BUDA carries a Unified Composite Score of 34.2/100 (SELL) at $5.30 (N/M Forward P/E, N/A operating margin), whereas LMRI carries 32.1/100 (SELL) at $14.26 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While BUDA currently prints a higher short-term Unified Composite Score (34.2/100 SELL vs. LMRI 32.1/100 SELL), LMRI captures the overall institutional head-to-head verdict (1–2 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY). Defensive Composite Rating Caution: Although LMRI compares more favorably head-to-head, both BUDA (34.2/100 SELL) and LMRI (32.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: BUDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.2); meanwhile LMRI trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BUDA and LMRI split Growth & Scale metrics: BUDA posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with LMRI at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, BUDA generates N/A in USD-normalized revenue versus N/A for LMRI. In operating R&D and SG&A reinvestment, BUDA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LMRI.

BUDA and LMRI trade at balanced relative valuation multiples. BUDA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas LMRI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BUDA (N/A ROE) versus LMRI (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, BUDA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.03β · 71% Vol realized risk). By comparison, LMRI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.22β · 85% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.